CYTOSORBENTS
CytoSorbents Corporation is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
CYTOSORBENTS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1997-01-01
Address:
Monmouth Junction, New Jersey, United States
Country:
United States
Website Url:
http://www.cytosorbents.com
Total Employee:
11+
Status:
Active
Contact:
7323298650
Total Funding:
22.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Board_member
2015-06-01
Current Employees Featured
Phillip P. Chan Chief Executive Officer and President @ Cytosorbents
Chief Executive Officer and President
2009-01-01
Vincent Capponi President @ Cytosorbents
President
2020-05-01
Vincent Capponi Chief Operating Officer @ Cytosorbents
Chief Operating Officer
2008-11-01
Eric Mortensen Chief Medical Officer @ Cytosorbents
Chief Medical Officer
2017-05-01
Kathleen Bloch Chief Financial Officer @ Cytosorbents
Chief Financial Officer
2013-05-01
Daniel Wendt VP, Medical Affairs Cardiovascular @ Cytosorbents
VP, Medical Affairs Cardiovascular
Efthymios Deliargyris Chief Medical Officer @ Cytosorbents
Chief Medical Officer
2020-05-01
Robert Bartlett Chief Medical Officer @ Cytosorbents
Chief Medical Officer
Founder
Stock Details
Investors List
Bridge Bank
Bridge Bank investment in Post-IPO Debt - Cytosorbents
U.S. Army Medical Research & Development Command
U.S. Army Medical Research & Development Command investment in Grant - Cytosorbents
Bridge Bank
Bridge Bank investment in Post-IPO Debt - Cytosorbents
Bridge Bank
Bridge Bank investment in Post-IPO Debt - Cytosorbents
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-21 | CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular |
| 2020-04-27 | Cytosorbents appoints chief medical officer |
Official Site Inspections
http://www.cytosorbents.com Semrush global rank: 4.29 M Semrush visits lastest month: 2.69 K
- Host name: 172.67.20.161
- IP address: 172.67.20.161
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cytosorbents"
CytoSorbents | Home
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care company specializing in blood purification to treat life-threatening conditions in the intensive care unit …See details»
Cytosorbents Corporation - Wikipedia
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. [2] [3] [4]CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark …See details»
Cytosorbents - Crunchbase Company Profile & Funding
CytoSorbents Corporation is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer …See details»
CytoSorbents Investor Relations
CytoSorbents Corporation is distributing its EU-approved CytoSorb cytokine adsorber in 75 countries around the world. CytoSorb® is helping to treat life-threatening conditions in the …See details»
CytoSorbents Corporation - LinkedIn
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption …See details»
Corporate Governance | CytoSorbents Investor Relations
CytoSorbents Corporate Governance. Governance Documents. Board Diversity 2024; Board Diversity 2023; Board Diversity 2022; Code of Business Conduct and Ethics; Corporate …See details»
CytoSorbents | Executive Management
Dr. Phillip Chan is the Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO). Over the past 16 years, Dr. Chan has led the company through the EU approval and …See details»
CytoSorbents - Overview, News & Similar companies - ZoomInfo
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation …See details»
Cytosorbents - Contacts, Employees, Board Members, Advisors
Organization. Cytosorbents . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 11. Number of Board …See details»
Liver - CytoSorbents
This area is for Health Care Professionals only and provides reports about clinical experiences gained during the use of CytoSorbents products. The information presented reflects the …See details»
CytoSorbents Company Profile - Craft
Oct 29, 2024 CytoSorbents is a company that engages in the research and development of medical devices. Its product includes VetResQ, a device for adjunctive therapy in the …See details»
Cytosorbents - Funding, Financials, Valuation & Investors
Cytosorbents is registered under the ticker NASDAQ:CTSO . Cytosorbents is funded by 4 investors. Avenue Capital Group and Bridge Bank are the most recent investors.See details»
CytoSorbents Launches International Campaign to Raise $100,000 …
CytoSorbents is proud to provide a 1:1 match on the anticipated generous donations from our network of employees, investors, partners, ... and is a 501(c)3 organization. About …See details»
CytoSorbents Unveils Newly Redesigned, Unified Company and
Jul 29, 2024 About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac …See details»
CytoSorb® Becomes a Featured Blood Purification Therapy on …
Aug 2, 2022 Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future …See details»
CytoSorbents Submits Health Canada Medical Device License …
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and …See details»
Our Innovation - CytoSorbents
CytoSorbents’ technology provides a powerful approach to hemoadsorption. And it all starts with a bead. All our solutions are based on our proprietary biocompatible, highly porous polymer …See details»
CytoSorbents | Studies and Registries
The CytoSorb Registries . The COSMOS (CytoSorb TreatMent OF Critically Ill PatientS) registry was opened in mid-2022 and is a company-sponsored international registry designed to …See details»
CytoSorbents Completes its Mission 100,000 International …
Jul 30, 2021 CytoSorbents to present a $100,000 check to CARE during the Opening Bell ceremony at NASDAQ today in New York City Times Square. MONMOUTH JUNCTION, N.J., …See details»
CytoSorbents Corporation Reports Estimated 22% to 25% Year
4 days ago CytoSorbents Corporation announced its preliminary financial results for the fourth quarter and full year of 2024, reporting an estimated 22% to 25% year-over-year growth in …See details»